Articles related to DRUG EFFICACY

Neoadjuvant apalutamide plus abiraterone and ADT before radical prostatectomy was associated with improved 12-month potency recovery and lower positive surgical margin rates compared with surgery alone in a small phase 2 trial of men with high-risk localized prostate cancer.

Two Lilly-sponsored placebo-controlled trials found that adults who transitioned from high-dose injectable GLP-1 therapy to either oral tirzepatide (Foundayo) or a reduced 5 mg tirzepatide maintenance dose preserved most of their prior weight loss over one year, compared to substantial regain in placebo arms.

Most newly diagnosed focal epilepsy patients required more than a year and more than one antiseizure medication to reach seizure freedom in a multicenter cohort.

A phase 3 head-to-head RCT of 689 patients found intravitreal brolucizumab preserved visual acuity at 54 weeks while panretinal photocoagulation patients lost a mean of approximately 4 letters, though intraocular inflammation rates were higher with brolucizumab.

Investigators surmised that current influenza vaccination programs provide substantial protection but could be further improved by strategies that could mitigate repeat vaccination effects.

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.